Bictegravir or dolutegravir (two integrase strand inhibitors) in combination with two nucleoside reverse transcriptase inhibitors are recommended as first-line antiretroviral therapy [1,2].Both have good tolerability, high efficacy, high barrier for resistance, and presentations that require only once-a-day dosing [3]. Raltegravir and efavirenz are alternative antiretroviral options that were previously recommended in antiretroviral treatment guidelines [1,2].
